PDSBHealthcare · BiotechnologyThe 2 Wall Street analysts covering PDS Biotechnology Corp. hold a median 12-month price target of $5 — +212.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 12 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores PDS Biotechnology Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (3): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PDSB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +212.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $7.00 → $5.00 |
| 26 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $7.00 |
| 26 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $15 → $7.00 |
| 13 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | $15 |
| 25 Nov 2025 | B. Riley Securities | Maintains | Buy | — |
| 13 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 July 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Nov 2024 | B. Riley Securities | Maintains | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PDSB appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Oct 2026, PDS Biotechnology Corp. returned +67.4% against +18.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 85% of US stocks
Cheaper than 98% of US stocks
Cheaper than 73% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 3% of US stocks
Higher than 5% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
PDS Biotechnology Corp. has a market value of $116.0M and an enterprise value of $83.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$33.7M.
Free cash flow in the twelve months to 30 June 2026: −$16.8M.
Trailing P/E: −2.2×; forward P/E: −4.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
PDS Biotechnology Corp. employs 21 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own PDS Biotechnology Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
PDS Biotechnology announced it will host a virtual key opinion leader event on PDS0301 for advanced colorectal cancer with liver metastases.
Why it matters — The event will provide information on the company’s PDS0301 program in this cancer setting.
PDS Biotech announced the publication of results from its VERSATILE-002 Phase 2 clinical trial of PDS0101 in combination with pembrolizumab for HPV16-positive recurrent and/or metastatic head and neck cancer in the September 17, 2026 issue of JAMA Oncology. The data showed 39.3 months median overall survival in first-line immune checkpoint inhibitor-naive patients, while the company continues to prioritize PDS0301 in metastatic colorectal cancer and pursue a partnership strategy for PDS0101.
Why it matters — This peer-reviewed publication in JAMA Oncology provides independent validation of PDS0101's Phase 2 efficacy data, which is significant for PDSB shareholders given the company's ongoing partnership efforts for the therapy.
PDS Biotechnology announced it has raised up to $22.55 million in equity funding through a private investment in public equity (PIPE) transaction, led by Dr. Patrick Soon-Shiong, founder of NantWorks. Dr. Soon-Shiong will join PDS Biotech's board of directors, and the company plans to progress development of its PDS0301 immunocytokine for solid tumors.
Why it matters — A PDSB watcher would care because the financing provides capital to advance its PDS0301 immunocytokine program and brings a prominent investor onto the board, which could support the company's clinical development efforts.
PDS Biotechnology Corporation reported its financial results for the quarter ended June 30, 2026, and provided a business and clinical programs update. The announcement was made in Princeton, N.J., on Aug. 13, 2026.
Why it matters — PDS Biotech watchers would care because the quarterly financial report and clinical programs update offer a current view of the company's cash position, expenditures, and pipeline progress.
PDS Biotechnology Corporation's shares fell by about 67% on Tuesday after the company announced a strategic refocus on its PDS0301 program for metastatic colorectal cancer.
Why it matters — PDSB watchers would care because the company is pivoting its strategy to a new program while its stock experienced a sharp one-day decline.
The 2 Wall Street analysts covering PDS Biotechnology Corp. have a median 12-month price target of $5, with estimates ranging from $5 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering PDS Biotechnology Corp., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PDS Biotechnology Corp. 78 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Oct 2026, PDS Biotechnology Corp. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +212.5% from the last close, and Ticker Nerd's factor model ranks PDS Biotechnology Corp. 78 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering PDS Biotechnology Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PDSB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $5 over the next 12 months.
PDS Biotechnology Corp. returned +67.4% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing immunotherapies that harness T cells to target cancer. Its current pipeline centers on the Versamune platform, which is designed to stimulate and direct immune responses against tumors, with programs spanning multiple oncology indications.
The most recent item we track (GlobeNewsWire, 6 Oct 2026): "PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases". PDS Biotechnology announced it will host a virtual key opinion leader event on PDS0301 for advanced colorectal cancer with liver metastases.
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing immunotherapies that harness T cells to target cancer. Its current pipeline centers on the Versamune platform, which is designed to stimulate and direct immune responses against tumors, with programs spanning multiple oncology indications. The company also works on tumor-targeted approaches that combine immune activation with precision delivery, supporting research across head and neck, cervical, prostate, anal, breast, and other cancers. PDS Biotechnology Corporation operates as a specialist in immuno-oncology, aiming to address areas where conventional treatments may be limited. Based in Princeton, New Jersey, the company focuses on advancing current product candidates through clinical development and commercialization efforts in the biopharmaceutical market.
CEO Dr. Frank K. Bedu-Addo Ph.D. · 21 employees · United States · https://www.pdsbiotech.com
